Thursday, December 7, 2017

Metacrine Lands $22M For Metabolic Disease Treatments

San Diego-based Metacrine, a biotechnology firm which is developing drugs for treating metabolic disease, has raised $22M in a Series B funding. The funding was led by New Enterprise Associates (NEA), and also included ARCH, Polaris, venBio, and Alexandria Venture Investments. NEA Partner Carol Gallagher will join the company's board as part of the funding. The company says it has now raised a total of $60M. More information »